Acromegaly

Amolyt Pharma Selected for the French Tech 120 Program

Retrieved on: 
Friday, February 4, 2022
Patient, SME, Hypoparathyroidism, Endocrinology, Twitter, Biotechnology, Program, Tech, Health, GLOBE, PTH, Acromegaly, Solution, Vichy, Fine chemical

LYON, France and CAMBRIDGE, Mass., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has been selected for the French Tech FT120, a support program for French late-stage startups by the French State.

Key Points: 
  • --The French Tech 120 list represents the 120 top performing and rapidly growing startups based in France across all industries, including 7 biotechnology companies developing innovative therapies--
    LYON, France and CAMBRIDGE, Mass., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has been selected for the French Tech FT120, a support program for French late-stage startups by the French State.
  • The French Tech 120 program identifies the 120 top-performing startups based in France.
  • The globally renowned reputation of the French Tech 120 program will greatly benefit the company by providing increased visibility and a range of services.
  • We look forward to building on our recent momentum to develop our company and to leveraging the French Tech 120 program and recognition.

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, February 1, 2022
Carcinoid syndrome, SAN, Nasdaq, Medication, Employment, Drug discovery, Congenital hyperinsulinism, Degenerative disease, ACTH, Financial compensation, GLOBE, Congenital adrenal hyperplasia, Therapy, Acromegaly, Wilms' tumor, Pharmaceutical industry

The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The 2021 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $18.84 per share, which is equal to the closing price of Crinetics common stock on The Nasdaq Global Select Market on February 1, 2022.
  • Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Notice of General Meeting

Retrieved on: 
Tuesday, February 1, 2022
EST, Forward-looking statement, Patient, General officer, Octreotide, Lipodystrophy, American depositary receipt, EMA, GL, Proxy, Lists of diseases, Lomitapide, Company, Annual general meeting, Environment, EB, COVID, Board, COVID-19, Companies Act 2006, Mass meeting, Health, Diet, Birth, Metreleptin, Time, Investment, FDA, 353, Acromegaly, Degenerative disease, Review, Nasdaq, Fine chemical, Holding company, Security (finance), Pharmaceutical industry, Dietary supplement, Junctional epidermolysis bullosa (medicine), EU

Copies of the notice for the General Meeting, when posted, will also be available on the Company's website, www.amrytpharma.com .

Key Points: 
  • Copies of the notice for the General Meeting, when posted, will also be available on the Company's website, www.amrytpharma.com .
  • The General Meeting is not an annual general meeting and the annual general meeting for the Company for 2022 will be held later in the year.
  • Shareholders are strongly encouraged to vote in advance of the General Meeting by appointing the Chairman of the General Meeting as their proxy.
  • This means that the Chairman of the General Meeting will be able to vote on their behalf, and in accordance with their instructions, at the General Meeting.

Amryt Announces Oleogel-S10 EMA Regulatory Update

Retrieved on: 
Friday, January 28, 2022
Risk, Committee, Infection, Physician, Skin, Environment, COVID-19, Diet, Metreleptin, Patient, Review, European Medicines Agency, CEO, Octreotide, EMA, Lomitapide, Lists of diseases, Company, Committee for Medicinal Products for Human Use, Birth, Investment, Acromegaly, Death, GL, Ulcer, FDA, Scar, Nasdaq, Forward-looking statement, Esophagus, Somatostatin, Lipodystrophy, Epidermolysis bullosa, Human, European Directive on Traditional Herbal Medicinal Products, Disease, Stenosis, Degenerative disease, Pharmaceutical industry, Dietary supplement, EU, Junctional epidermolysis bullosa (medicine), EB

The European Medicines Agency (EMA) review process for Oleogel-S10 in EB is ongoing and Amryt has responded to outstanding questions.

Key Points: 
  • The European Medicines Agency (EMA) review process for Oleogel-S10 in EB is ongoing and Amryt has responded to outstanding questions.
  • The Committee for Medicinal Products for Human Use (CHMP) opinion is now anticipated in March 2022.
  • Dr Joe Wiley, CEO of Amryt Pharma, commented: We welcome the input from independent EB physicians and importantly the voice of EB patients, via the Ad-Hoc Expert Group to assist the EMA progress its regulatory assessment of Oleogel-S10.
  • Amryt alsointends to develop oral medications that are currently only available as injectable therapies through itsTransient PermeabilityEnhancer (TPE) technology platform.For more information on Amryt, including products, please visit www.amrytpharma.com .

Amryt Announces New Patents for Oleogel-S10

Retrieved on: 
Tuesday, January 18, 2022
Forward-looking statement, Orange Book, Patient, Food and Drug Administration, Approved drug, EMA, EB, Birth, COVID-19, Degenerative disease, Lists of diseases, Lipodystrophy, CEO, Diet, Review, Acromegaly, Nasdaq, Patent, Lesbian flag, Environment, Investment, GL, Approved Drug Products with Therapeutic Equivalence Evaluations, United States Patent and Trademark Office, Food, Lomitapide, Octreotide, FDA, United States patent law, Somatostatin, Metreleptin, Pharmaceutical industry, Dietary supplement, EU, Junctional epidermolysis bullosa (medicine)

The United States Patent and Trademark Office (USPTO) has issued to Amryt a notice of allowance for US Patent Application No.

Key Points: 
  • The United States Patent and Trademark Office (USPTO) has issued to Amryt a notice of allowance for US Patent Application No.
  • Amryt alsointends to develop oral medications that are currently only available as injectable therapies through itsTransient PermeabilityEnhancer (TPE) technology platform.For more information on Amryt, including products, please visit www.amrytpharma.com .
  • The forward-looking statements in this announcement are based on numerous assumptions and Amryt's present and future business strategies and the environment in which Amryt expects to operate in the future.
  • Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 12, 2022
Biomarker, Securities Exchange Act of 1934, Patient, Research, Annual report, Conference, SAN, SEC, NETS, Form 10-K, Congenital adrenal hyperplasia, CEO, MAD, Carcinoid syndrome, Degenerative disease, GLOBE, IND, Wilms' tumor, Acromegaly, Malignancy, Nasdaq, Hyperparathyroidism, SST2, Program, PTHR1, Drug development, Therapy, Congenital hyperinsulinism, Drug Quality and Security Act, Drug discovery, ACTH, Securities Act of 1933, Pharmaceutical industry

SAN DIEGO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Scott Struthers, Ph.D., founder & CEO of Crinetics, will provide a company update at the 40th annual J.P. Morgan Healthcare Conference today, Wednesday, January 12th at 4:30 PM Eastern Time / 1:30 PM Pacific Time. A live audio webcast of Dr. Struthers’ presentation may be accessed on the Events page of the company’s website.

Key Points: 
  • A live audio webcast of Dr. Struthers presentation may be accessed on the Events page of the companys website.
  • During his presentation, Dr. Struthers will discuss Crinetics key priorities and anticipated milestones for 2022.
  • Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
  • Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors.

DALI Medical's SAN®Light Passive Safety Needle coupled with a novel Drug Product, Enabling User-friendly Administration

Retrieved on: 
Wednesday, January 12, 2022
Patient, SAN, TEL, Perception, Advanz Pharma, Safety, CEO, Injection, Luer, Acromegaly, View, Pain, Anxiety, Multimedia, DALI, Medical device, Fine chemical, EU

TEL AVIV, Israel, Jan. 12, 2022 /PRNewswire/ -- DALI Medical Devices, an innovative developer and distributor of drug delivery devices, today announced the first commercial implementation of its SAN-Light passive safety needle.

Key Points: 
  • TEL AVIV, Israel, Jan. 12, 2022 /PRNewswire/ -- DALI Medical Devices, an innovative developer and distributor of drug delivery devices, today announced the first commercial implementation of its SAN-Light passive safety needle.
  • ADVANZ's product incorporates a prefilled syringe and a special version of SAN-Light needle that was customized to fit to the drug' parameters and users' needs.
  • SAN-Light is a unique, single-use sterile hypodermic safety needle that is compatible with any Luer-lock syringe for subcutaneous or intramuscular drug administration.
  • The automatically activated (passive) needle shield reduces needle-stick injuries, and the partially hidden needle alleviates needle anxiety.

DALI Medical's SAN®Light Passive Safety Needle coupled with a novel Drug Product, Enabling User-friendly Administration

Retrieved on: 
Wednesday, January 12, 2022
Patient, SAN, TEL, Perception, Advanz Pharma, Safety, CEO, Injection, Luer, Acromegaly, Pain, Anxiety, DALI, Medical device, Fine chemical, Pharmaceutical industry, EU

TEL AVIV, Israel, Jan. 12, 2022 /PRNewswire/ -- DALI Medical Devices, an innovative developer and distributor of drug delivery devices, today announced the first commercial implementation of its SAN-Light passive safety needle.

Key Points: 
  • TEL AVIV, Israel, Jan. 12, 2022 /PRNewswire/ -- DALI Medical Devices, an innovative developer and distributor of drug delivery devices, today announced the first commercial implementation of its SAN-Light passive safety needle.
  • ADVANZ's productincorporates a prefilled syringe and a special version of SAN-Light needle that was customized to fit to the drug' parameters and users' needs.
  • SAN-Light is a unique, single-use sterile hypodermic safety needle that is compatible with any Luer-lock syringe for subcutaneous or intramuscular drug administration.
  • The automatically activated (passive) needle shield reduces needle-stick injuries, and the partially hidden needle alleviates needle anxiety.

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide

Retrieved on: 
Tuesday, January 11, 2022
RCT, SRL, Oregon Health Plan, Patient, Oregon Health & Science University, Oregon Health and Science University Center for Women's Health, EMA, Union, Degenerative disease, Safety, Adult, GI, Emotion, GH, Randomized controlled trial, FACE, Neurosurgery, Cabergoline, Treatment, OLE, Maintenance, Pharmaceutical industry, Medical device, Acromegaly

- Patients switching from injectable Somatostatin Receptor Ligands (iSRLs) to Mycapssa during the OLE reported improved acromegaly symptom control on Mycapssa.

Key Points: 
  • - Patients switching from injectable Somatostatin Receptor Ligands (iSRLs) to Mycapssa during the OLE reported improved acromegaly symptom control on Mycapssa.
  • Mycapssa is approved in the United States for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with injectable octreotide or lanreotide.
  • Mycapssa (oral octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
  • Mycapssa (oral octreotide) is approved in the US for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Key Dates for AIM Delisting

Retrieved on: 
Thursday, January 6, 2022
EMA, Lists of diseases, COVID-19, AIM, Acromegaly, Degenerative disease, Review, ADS, Company, Environment, Patient, Citibank, Common stock, Forward-looking statement, Diet, ADSS, American depositary receipt, Lipodystrophy, Metreleptin, Stifel, FDA, Press Corporation Limited, NOMAD, EB, Birth, SDRT, GL, Investment, Lomitapide, Octreotide, Pharmaceutical industry, Security (finance), Financial adviser, Communications satellite, Dietary supplement, Junctional epidermolysis bullosa (medicine), EU, Nasdaq

As previously announced, the last day of trading in the Company's Ordinary Shares on AIM will be January 10, 2022 and the proposed AIM Delisting will be effective from 7.00 a.m. (London time) on January 11, 2022.

Key Points: 
  • As previously announced, the last day of trading in the Company's Ordinary Shares on AIM will be January 10, 2022 and the proposed AIM Delisting will be effective from 7.00 a.m. (London time) on January 11, 2022.
  • Following the AIM Delisting, the Company's ADSs will remain listed, and will only be tradeable, on Nasdaq.
  • Following the AIM Delisting, Shore Capital and Corporate Limited will cease to act as nominated adviser to the Company.
  • The below expected timetable for the AIM Delisting is unchanged from that announced on November 22, 2021.